These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 19897041)

  • 1. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
    Meek DW; Hupp TR
    Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
    Stommel JM; Wahl GM
    Cell Cycle; 2005 Mar; 4(3):411-7. PubMed ID: 15684615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
    Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
    Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
    Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
    J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53 response to DNA damage.
    Meek DW
    DNA Repair (Amst); 2004; 3(8-9):1049-56. PubMed ID: 15279792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
    Di Cintio A; Di Gennaro E; Budillon A
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
    Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
    Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
    Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
    Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse modelling of the MDM2/MDMX-p53 signalling axis.
    Tackmann NR; Zhang Y
    J Mol Cell Biol; 2017 Feb; 9(1):34-44. PubMed ID: 28096294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
    Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
    Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.